Angiosarcomas and Other Sarcomas of Endothelial Origin

Cioffi, Angela; Reichert, Sonia; Antonescu, Cristina R.; Maki, Robert G.

doi:10.1016/j.hoc.2013.07.005

Cited by 34 publications

(34 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Blood glucose and blood pressure were within normal ranges during therapy. We may explain these results with the use of very small dose of corticosteroid (1 mg/kg per injection), supporting what is reported in the literature that these complications increased with the use of larger doses and long duration of corticosteroid therapy [21][22][23].…”

Section: Discussionsupporting

confidence: 85%

Five years’ experience of combined intralesional therapy in infantile hemangioma

Helal

Daboos

2019

Ann Pediatr Surg

View full text Add to dashboard Cite

Background: Infantile hemangiomas (IHs) are common vascular tumors. Although it involutes spontaneously, outcomes are unpredictable. Intralesional therapy is one of its treatment modality. We present our experience with combined intralesional therapy for IHs over a 5-year duration. A total of 427 patients were treated and followed at Al-Azhar University Hospitals during the study period of 5 years. All patients were treated by intralesional therapy in the form of combined injection of triamcinolone and bleomycin. All patients were followed for the response. Response to the treatment was graded as marked, partial, and poor improvement. Results: IHs were noticed within the first month of life in 90.2% of patients. The commonest site of involvement was head and neck in 90% of patients. The commonest clinical presentation was swelling with discoloration. Mean age was 7.43 ± 6.04 months and mean IHs size was 15.54 ± 11.13 cm 2. The response to the treatment was highest for patients below 1 year of age. The reported complications were ulceration, scarring, and subcutaneous atrophy in some cases. Conclusion: Combined intralesional therapy in IHs showed good efficacy in most patients. It is a reliable and safe treatment modality with clear curative effects and minimal complications. If IHs treatment is indicated, combined intralesional therapy should be considered as an alternative effective treatment modality.

show abstract

Section: Discussionsupporting

confidence: 85%

Five years’ experience of combined intralesional therapy in infantile hemangioma

Helal

Daboos

2019

Ann Pediatr Surg

View full text Add to dashboard Cite

show abstract

“…These tumors can arise secondary to radiation therapy for other cancers or chronic lymphedema (3) . Other known risk factors include UV irradiation, given the typical locations of cutaneous angiosarcomas on the head and neck (10)(11)(12) , as well as occupational exposure to vinyl chloride (13) , arsenicals, and use of anabolic steroids (14) . Genetically, angiosarcoma is associated with familial syndromes including Li-Fraumeni syndrome ( TP53 mutations) (15) and Klippel-Trenaunay syndrome ( PIK3CA mutations) (16) .…”

Section: Introductionmentioning

confidence: 99%

Genomic analysis reveals shared genes and pathways in human and canine angiosarcoma

Megquier

Turner-Maier

Swofford

et al. 2019

Preprint

View full text Add to dashboard Cite

Angiosarcoma is a highly aggressive cancer of blood vessel-forming cells with high fatality and few effective treatment options. It is both rare and heterogenous, making large, well powered genomic studies nearly impossible. In dogs, angiosarcoma is common, with breeds like the golden retriever carrying heritable genetic factors that put them at very high risk. If the clinical similarity of canine and human angiosarcoma reflects shared genomic etiology, dogs could be a critically needed model for advancing angiosarcoma research. We assessed the genomic landscape of canine angiosarcoma via whole exome sequencing (47 golden retriever angiosarcomas) and RNA sequencing (74 angiosarcomas from multiple breeds). The predominant mutational signature was the age-associated deamination of cytosine to thymine, and somatic coding mutations occurred most frequently in the tumor suppressor TP53 (59.6% of cases) as well as two genes in the PI3K pathway: the oncogene PIK3CA (29.8%) and its regulatory subunit PIK3R1 (8.5%). We compared the canine data to human data recently released by The Angiosarcoma Project, and found the same genes and many of the same pathways significantly enriched for somatic mutations, most notably protein kinases, glycoproteins, fibronectin Type III domains, EGF-like domains, and cell adhesion proteins such as cadherins. As in human angiosarcoma, CDKN2A/B was recurrently deleted and VEGFA, KDR, and KIT recurrently gained. Canine angiosarcoma closely models human angiosarcoma on a genomic level, and is a powerful tool for investigating the pathogenesis of this devastating disease. Canine only PI3K pathway PIK3CG

show abstract

“…Thus, the outcomes of people and dogs are not likely to improve without an increased understanding of the biology and pathogenesis of these tumors. To complicate matters further, angiosarcomas occur infrequently restricting the study of their basic biology and clinical treatment [ 3 ]. However, the frequent occurrence of hemangiosarcomas in dogs (up to 7% of all canine malignancies) [ 4 ] provides a readily available resource to investigate tumor biology and explore related treatment options.…”

Section: Introductionmentioning

confidence: 99%

Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression

et al. 2014

View full text Add to dashboard Cite

BackgroundHuman angiosarcoma and canine hemangiosarcoma are thought to arise from vascular tissue or vascular forming cells based upon their histological appearance. However, recent evidence indicates a hematopoietic or angioblastic cell of origin for these tumors. In support of this idea, we previously identified an endothelial-myeloid progenitor cell population with high expression of endothelial cell markers and the myeloid cell marker, colony stimulating factor 1 receptor (CSF-1R). Here, we further characterized these cells to better understand how their cellular characteristics may impact current therapeutic applications.MethodsWe performed cell enrichment studies from canine hemangiosarcoma and human angiosarcoma cell lines to generate cell populations with high or low CSF-1R expression. We then utilized flow cytometry, side population and cell viability assays, and fluorescence based approaches to elucidate drug resistance mechanisms and to determine the expression of hematopoietic and endothelial progenitor cell markers.ResultsWe demonstrated that cells with high CSF-1R expression enriched from hemangiosarcoma and angiosarcoma cell lines are more drug resistant than cells with little or no CSF-1R expression. We determined that the increased drug resistance may be due to increased ABC transporter expression in hemangiosarcoma and increased drug sequestration within cellular lysosomes in both hemangiosarcoma and angiosarcoma.ConclusionsWe identified drug sequestration within cellular lysosomes as a shared drug resistance mechanism in human and canine vascular sarcomas marked by high CSF-1R expression. Taken together, our results demonstrate that studies in highly prevalent canine hemangiosarcoma may be especially relevant to understanding and addressing drug resistance mechanisms in both the canine and human forms of this disease.

show abstract

Angiosarcomas and Other Sarcomas of Endothelial Origin

Cited by 34 publications

References 79 publications

Five years’ experience of combined intralesional therapy in infantile hemangioma

Five years’ experience of combined intralesional therapy in infantile hemangioma

Genomic analysis reveals shared genes and pathways in human and canine angiosarcoma

Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression

Contact Info

Product

Resources

About